Mizuho reiterated their neutral rating on shares of Mallinckrodt (NYSE:MNK) in a research note published on Tuesday morning, Marketbeat Ratings reports. Mizuho currently has a $21.00 price objective on the stock, down from their prior price objective of $22.00.
Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Mallinckrodt from a sell rating to a hold rating in a research note on Tuesday, October 31st. Canaccord Genuity set a $24.00 price objective on Mallinckrodt and gave the company a hold rating in a research note on Tuesday, November 14th. Cantor Fitzgerald set a $42.00 target price on Mallinckrodt and gave the company a buy rating in a report on Tuesday, December 26th. Wells Fargo & Co reissued a hold rating on shares of Mallinckrodt in a report on Monday, January 1st. Finally, Oppenheimer dropped their target price on Mallinckrodt from $70.00 to $48.00 in a report on Tuesday, September 19th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $44.99.
Shares of Mallinckrodt (MNK) traded up $0.60 during midday trading on Tuesday, hitting $23.50. The stock had a trading volume of 2,473,100 shares, compared to its average volume of 3,190,000. The firm has a market capitalization of $2,230.00, a PE ratio of -1,175.00, a P/E/G ratio of 0.43 and a beta of 1.30. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. Mallinckrodt has a twelve month low of $19.00 and a twelve month high of $55.32.
In other news, Director David R. Carlucci acquired 10,000 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $21.83 per share, with a total value of $218,300.00. Following the completion of the acquisition, the director now owns 26,020 shares in the company, valued at approximately $568,016.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Mark Trudeau acquired 5,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were purchased at an average cost of $22.28 per share, for a total transaction of $111,400.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 30,460 shares of company stock worth $659,486. Corporate insiders own 0.77% of the company’s stock.
Several hedge funds have recently modified their holdings of MNK. HealthCor Management L.P. purchased a new position in shares of Mallinckrodt during the second quarter worth about $107,649,000. Janus Henderson Group PLC grew its holdings in shares of Mallinckrodt by 6,828.1% during the second quarter. Janus Henderson Group PLC now owns 1,396,780 shares of the company’s stock worth $62,590,000 after purchasing an additional 1,376,619 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Mallinckrodt by 117.3% during the second quarter. Ameriprise Financial Inc. now owns 1,937,444 shares of the company’s stock worth $86,815,000 after purchasing an additional 1,045,757 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of Mallinckrodt by 114.9% during the third quarter. Prudential Financial Inc. now owns 1,379,978 shares of the company’s stock worth $51,569,000 after purchasing an additional 737,791 shares during the last quarter. Finally, AJO LP grew its holdings in shares of Mallinckrodt by 165.6% during the second quarter. AJO LP now owns 927,472 shares of the company’s stock worth $41,560,000 after buying an additional 578,266 shares during the last quarter. 97.35% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/01/14/mallinckrodt-mnk-rating-reiterated-by-mizuho.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.